Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody‐mediated phagocytosis in cancer immunotherapy

21 Aug 2023

Abstract excerpt

SUMMARY Unconjugated monoclonal antibodies (mAbs) have revolutionized the treatment of many types of cancer. Some of these mAbs promote the clearance of malignant cells via direct cytotoxic effects. More recently, antibody‐dependent cellular phagocytosis (ADCP) has been appreciated as a major mechanism of action for a number of widely used mAbs, including anti‐CD20 (rituximab, obinutuzumab), anti‐HER2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Complement system in diseases
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37602915
DOI: 10.1111/imr.13265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody‐mediated phagocytosis in cancer immunotherapyPMID 37602915Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

A three dimensional human immune-tumor cell model reveals the importance of isotypes in antibody-based immunotherapySemantic proximity Read ↗

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity Read ↗

Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy.Semantic proximity Read ↗

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer PatientsSemantic proximity Read ↗

Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2Semantic proximity Read ↗

Biological impediments to monoclonal antibody–based cancer immunotherapySemantic proximity Read ↗

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burdenSemantic proximity Read ↗

Isotype selection for antibody-based cancer therapySemantic proximity Read ↗

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapySemantic proximity Read ↗

Anti-CD19/CD20 bispecific antibody with dual Fc domains mediates enhanced effector functions and durable depletion of memory B cells in vivoSemantic proximity Read ↗

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.